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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.003Abstract Pulmonary alveolar proteinosis (PAP), characterized by deposition of intra-alveolar PAS positive
protein and lipid rich material, is a rare cause of progressive respiratory failure first described by Rosen
et al. in 1958. The intra-alveolar lipoproteinaceous material was subsequently proven to have been derived
from pulmonary surfactant in 1980 by Singh et al. Levinson et al. also reported in 1958 the case of 19-
year-old female with panmyelosis afflicted with a diffuse pulmonary disease characterized by filling of the
alveoli with amorphous material described as ‘‘intra-alveolar coagulum’’. This is probably the first reported
case of PAP in relation to hematologic malignancy. Much progress has been made on PAP first described
by Rosen which is currently classified as idiopathic or primary or autoimmune PAP. Idiopathic PAP occurs
as a result of auto-antibodies directed against granulocyte–macrophage colony stimulating factor (GM-CSF)
impeding the surfactant clearing function of alveolar macrophages leading to progressive respiratory failure.
Whole lung lavage and GM-CSF therapy has improved outcomes in patients with idiopathic PAP. Despite
major advancement in the management of hematologic malignancy and its complications, little is known
about the type of PAP first described by Levinson and now known as secondary PAP; a term also used
when PAP occurs due to other causes such as occupational dusts. In this article we review and analyze
the limited literature available in secondary PAP due to hematologic malignancies and present a case
of PAP associated with chronic lymphocytic leukemia successfully treated with bendamustine and
rituximab.
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infections; Hematopoietic stem cell transplantationPulmonary alveolar proteinosis (PAP) is a raredisorder in which excess surfactant accumu-lates within pulmonary alveoli, causing cough,
progressive dyspnea and respiratory insufﬁciency.1,2
PAP was ﬁrst reported in 1958 as a series of 27 cases
collected from multiple institutions over a period of
ﬁve years.1 PAP occurs in three clinically distinct
forms: congenital, secondary, and primary (idiopathic
or autoimmune). Congenital PAP is the rarest form,
occurring due to mutations in the genes encoding
the granulocyte–macrophage colony stimulatingfactor (GM-CSF) receptor or the surfactant
proteins.3,4 Primary PAP is the most common form
(90% of PAP cases) and is considered an autoim-
mune disease due to its association with a high titer
of anti-GM-CSF autoantibodies. The autoantibodies
neutralize the biologic activity of GM-CSF and
impair the clearance of pulmonary surfactant by
alveolar macrophages, leading to the accumulation of
surfactant proteins and cellular debris in the alveolar
space, and thus diminishing gas exchange.2,4 Second-
ary PAP occurs in association with cancers (most127
Table 1. Reported secondary PAP in association with hematological
disorders/malignancies.
Myeloid disorders
 Myelodysplastic syndrome (MDS): most common
 Chronic myeloid leukemia (CML): second most
common
 Overlap myeloproliferative neoplasm (MPN/MDS)
 Chronic myelomonocytic leukemia (CMML)
 Acute myeloid leukemia (AML)
 Primary myelofibrosis
 Polycythemia vera (PV)
 Essential thrombocytosis (ET)
Lymphoid disorders
 Acute lymphoid leukemia (ALL)
 Lymphoma (Hodgkin’s and Non-Hodgkin’s)
 Adult T cell leukemia/lymphoma
 Thymic alymphoplasia
 Cutaneous T cell lymphoma
 Chronic lymphocytic leukemia
Miscellaneous hematologic conditions
 Fanconi’s anemia
 Aplastic anemia
 Congenital dyserythropoietic anemia
 Multiple myeloma/plasmacytoma
 Idiopathic thrombocytopenic purpura (ITP)
Non-hematologic malignancies
 Glioblastoma
 Lung cancer
 Mesothelioma
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commonly hematologic malignancies), inhalational
exposure to certain occupational dusts (silica, alumi-
num, titanium, indium), within the setting of immu-
nosuppression after solid organ transplant or
allogeneic hematopoietic stem cell transplantation
(allo-SCT), or in relation to certain infections such
as human immunodeﬁciency virus (HIV).2–6 In
1958, Levinson et al. reported the case of a 19-year-
old female with myeloproliferative disorder dying
from a progressive respiratory illness compounded
by pulmonary aspergillosis with pre-mortem biopsy
and autopsy of the lungs showing distended alveoli
described as ‘‘non-cellular acidophilic intra-alveolar
coagulum,’’ consistent with PAP by today’s standard.7
This is probably the ﬁrst reported association of
hematologic malignancy to PAP and opportunistic
infection. This report was followed by a description
in 1963 of two autopsy cases by Doyle et al.8 and a
more systematic autopsy series of ﬁve cases by Carno-
vale et al.9 in 1977 indicating that the association of
PAP, hematologic malignancies and opportunistic
infection was more than just a coincidence. In 1980,
Singh and Katyal proved that lipoproteinaceous
intra-alveolar accumulation in primary PAP is derived
from the surfactants produce by the type II pneumo-
cytes.10 The modern pathogenesis of primary PAP is
based on the discovery that bi-allelic GM-CSF
knocked down mice (GM-CSF/) had normal
hematopoiesis but developed a pulmonary disease
strikingly similar to PAP, which established the piv-
otal role of the GM-CSF signaling pathway for the
pathogenesis of PAP.11,12 However, the GM-CSF
pathway appears to be uninvolved in PAP secondary
to hematologic malignancy (HPAP), and its exact
pathogenic mechanism remains unknown.
HPAP remains a rare disorder of unclear etiology
limited to case reports and small series. HPAP has
been reported in association with a wide range of
hematologic disorders (Table 1), with a majority of
cases occurring in association with hematological
malignancies of myeloid origin.2–6 Why this disorder
has a predilection for myeloid neoplasms and myelo-
dysplastic syndrome (MDS) is unknown, but one
hypothesis includes reduced macrophage number or
function due to the primary disease or its therapy
or both.5,6 Unlike the primary form, the PAP in
hematologic malignancy (HPAP) is not associated
with development of GM-CSF auto-antibodies.5,6
The exact incidence of HPAP is unknown. However,
one small, retrospective series showed that it could be
responsible for up to 5% of pulmonary symptoms in
hematologic malignancies.6 A large database of 404
patients with PAP in Japan showed that 40 patients(10%) had HPAP secondary to underlying hemato-
logical malignances and all of the 40 cases were nega-
tive for anti-GM-CSF antibody.6 This suggests the
existence of a non-antibody mediated and possibly a
cellular immune mechanism of HPAP. In most
reported cases of HPAP, the diagnosis was often
missed prior to autopsy because PAP was rarely sus-
pected prior to the death of patients.5,6 Thus, PAP is
usually considered a lethal complication of hemato-
logic malignancies, though its transient and reversible
nature has been reported in association with remis-
sion of underlying hematologic malignancy, either
from chemotherapy or after hematopoietic stem cell
transplants.5,6 Resolution is thought to result from
immune reconstitution and recovery of alveolar mac-
rophage function after treatment of hematologic
malignancy, and recovery of leukopenia and tapering
or discontinuation of immunosuppressive therapy.
Here we present a case of PAP in the setting
of chronic lymphocytic leukemia (CLL) and review
the limited literature available in patients with
HPAP.Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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A 69-year-old man was diagnosed with CLL during a
routine clinical evaluation at an external hospital. He
was asymptomatic, but was managed expectantly over
the next four years, until he presented with fevers,
exertional dyspnea, and night sweats. He was diag-
nosed with atypical, community-acquired pneumonia
based on a chest X-ray that showed bilateral, intersti-
tial and parenchymal opacities for which he received a
two-week course of levoﬂoxacin. The symptoms
improved somewhat, but a repeat chest X-ray after
six weeks showed no improvement. The patient then
presented to Tufts Medical Center (TMC) with high
grade fever, biopsy-proven leukemia cutis causing
nodular skin lesions, a swollen right knee joint with
synovial ﬂuid growing Pseudomonas aeruginosa, and
pseudomonal sepsis. Complete blood count revealed
WBC 13,500/mm3, hemoglobin 9.6 g/dL, platelets
64,000/mm3, absolute neutrophil count, 200/mm3,
absolute lymphocyte count 12,200/mm3, and absolute
monocyte count 0/mm3. Computed tomography
(CT) scan of thorax revealed bilateral parenchymal
pulmonary opacities (Figure 1A) and bronchoscopy
with bronchoalveolar lavage (BAL) revealed 12 cc of
pinkish ﬂuid that was negative for bacteria, fungi,
mycobacteria, Pneumocystis jiroveci and cytomegalovi-A B
D 
Figure 1. A. Thoracic CT scan at presentation showing ground-glass opac
rituximab showing interval worsening of pulmonary parenchymal disease
6 months post-bendamustine and rituximab showing generalized improv
(autoimmune) PAP showing bilateral geographic ground-glass opacities (GG
pattern'' in both lung fields.
Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014rus. BAL ﬂuid differential cell count showed 83%
lymphocytes, 12% neutrophils and 5% monocytes/
macrophages. The patient remained febrile with per-
sistent left upper quadrant abdominal pain even after
completing a course of cefepime for pseudomonal bac-
teremia, prompting an abdominal CT scan that
revealed hepatosplenomegaly and multiple splenic
hypodensities suspicious for visceral candidiasis. He
was additionally treated with IV micafungin followed
by maintenance ﬂuconazole with subsequent deferves-
cence. A bone marrow biopsy showed extensive
involvement (>90%) by a monotypic population of
B cells expressing CD19, dim CD20, dim CD5,
CD23, lambda light chains, and negative for CD5
and CD38. Cytogenetic analysis by ﬂorescent in situ
hybridization (FISH) demonstrated trisomy 12.
Once the infections were controlled, the patient
was treated with bendamustine and rituximab (B–R)
for CLL. After two cycles of B–R, he responded with
clearing of CLL in the peripheral blood, and
resolution of hepatosplenomegaly and generalized
lymphadenopathy. However, he experienced interval
worsening of pulmonary parenchymal disease with
increasing linear and ground glass densities
throughout both lungs (Figure 1B). Serology for
aspergillus galactomannan antigen index in both
blood and BAL was 0.1 (<0.5 is considered negative).C
ities reported as multifocal pneumonia. B. Thoracic CT scan after 2 cycles of bendamustine and
with increasing linear and ground-glass densities throughout both lungs. C. Thoracic CT scan
ement in the pulmonary densities. D. Thoracic CT scan of a different patient with idiopathic
O) with inter-lobular septal thickening, creating a characteristic mosaic or so called ``crazy paving
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Figure 2. Morphologic e
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Pulmonary function test (PFT) showed mild restric-
tive ventilatory defect with normal diffusion capacity.
Though the patient was feeling better and had only
mild dyspnea on exertion, a repeat ﬂexible bronchos-
copy with BAL of right middle lobe was performed.
Approximately 30 cc of milky ﬂuid analyzed revealed
no neoplastic or infectious process but showed large
aggregates of cast-like granular material, staining
positively for periodic acid-Schiff stain (PAS) and
resistant to diastase, highly suggestive of pulmonary
alveolar proteinosis (PAP). GMS stain was negative
for fungus or P. jiroveci and FITE stain was negative
for Nocardia. BAL differential cell counts showed
lymphocytes 39%, neutrophils 3% and monocytes/
macrophage 56%. Video-assisted thoracoscopic
surgery (VATS) and wedge biopsies of right upper,
middle and lower lobes were performed. Morphologic
examination of the lung tissue revealed panlobular dif-
fuse areas of intra-alveolar granular material consistent
with PAP (Figure 2 arrow). In addition, a small focus
with intra-alveolar fungal hyphae morphologically
consistent with aspergillus species and associated
areas of organizing pneumonia pattern of lung injury
possibly secondary to tissue invasion by the aspergillus
was identiﬁed. In limited areas predominantly in
subpleural location, very small aggregates of CD20
positive B-cells co-expressing CD5 were present.
This is consistent with minimal residual involvement
by the patient’s known CLL. Neutralizing autoanti-
body against GM-CSF in the serum was not detected
and the serum GM-CSF level was not elevated
(<3 pg/ml).xamination of the lung tissue derived from video-assisted transthoracic sur
ive (PAS positive) material (arrow) and preserved alveolar septal architectuThroughout the course of B–R therapy, the
patient was supported by exogenous G-CSF, pneu-
mocystis pneumonia prophylaxis with trimetho-
prim/sulfamethoxazole and immune prophylaxis
with intravenous immune globulin for depressed
IgG level of 334 mg/dL (normal range 562–
1585 mg/dL). The patient continued to do well fol-
lowing four cycles of B–R and a six-month course
of voriconazole for pulmonary aspergillosis, with com-
plete resolution of dyspnea. A CT scan obtained six
months (Figure 1C) following completion of four
cycles of B–R showed marked improvement of the
lung abnormalities. He is currently two years post-
chemo-immunotherapy (B–R) and remains asymp-
tomatic. It is possible that the patient’s presenting
symptoms and the radiographic ﬁndings of ‘‘atypical
pneumonia’’ may have been due to PAP but inﬁltra-
tion by CLL or opportunistic infection with or with-
out coexisting PAP cannot be ruled out.DISCUSSION
This case illustrates several important features of
PAP in hematologic malignancy (HPAP). First,
though PAP is predominantly associated with mye-
loid malignancies,5,6 it can also – though rarely as
in this case – occur in association with lymphoid
malignancies including CLL (Table 1). Second,
HPAP can be mistaken for atypical pneumonia, but
persistent symptoms and non-resolving radiologic
inﬁltrates after appropriate antibiotic therapy should
raise suspicion for HPAP. Third, HPAP can havegery (VATS) reveals alveolar filling with acellular, granular, eosinophilic,
re, consistent with a diagnosis of pulmonary alveolar proteinosis (PAP).
Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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onset prior to starting chemotherapy, and therefore is
not always due to the direct toxicity of chemotherapy
as has been proposed.5,6 Fourth, HPAP can improve
with treatment of underlying hematologic malignancy,
suggesting that this is a reversible complication and is
sensitive to the immunomodulatory effects of therapy.
Fifth, this case also highlights the importance of
including HPAP in the differential diagnosis of pro-
gressive respiratory symptoms and radiographic
changes in patients with hematologic malignancies
and underscores the importance of alerting the
pathologist to include appropriate staining (PAS
staining) of BAL ﬂuid or lung biopsy specimens to
conﬁrm the diagnosis. Sixth, CLL, HPAP and oppor-
tunistic infections (e.g. pulmonary aspergillosis) often
coexist, and making a diagnosis of HPAP should not
preclude the search for an associated pathogen. Every
attempt should be made to identify and treat such an
infection. After two cycles of B-R, our patient had
excellent response to CLL but developed worsening
pulmonary CT ﬁndings. We continued both CLL
directed and aspergillosis-speciﬁc therapy until grad-
ual improvement of dyspnea and eventual clearing of
the inﬁltrates. This case sheds light on the importance
of addressing both the hematologic malignancy and
the opportunistic infection for successful outcome.
Seventh, the fairly sensitive and speciﬁc serum galac-
tomannan assay with utility for early diagnosis and
prognostic value for pulmonary aspergillosis can be
falsely negative in patients with HPAP.13 Whether
the opportunistic infection is a cause or consequence
of PAP is unknown. Finally, lymphocytes were the
predominant cell type in the ﬁrst BAL, but mono-
cytes/macrophages were the main type of cells in
the second BAL. The difference of predominant cell
types between the ﬁrst and the second BAL is inter-
esting, and could reﬂect lymphocyte inﬁltration of
alveolar spaces by untreated CLL in the ﬁrst BAL
and possible immune reconstitution of alveolar mono-
cytes/macrophages by chemoimmunotherapy after
two cycles of B-R. Rituximab immunotherapy is also
known to cause depletion of lymphocytes.CLINICAL, LABORATORY, PATHOLOGIC
AND RADIOGRAPHIC MANIFESTATIONS
OF PULMONARY ALVEOLAR
PROTEINOSIS SECONDARY TO
HEMATOLOGIC MALIGNANCIES (HPAP)
A search of our internal database in this referral cen-
ter (TMC) for diagnosis and management of hemato-
logic malignancies revealed one additional case ofHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014HPAP occurring in association with an MDS patient
in the last 15 years. Others have estimated that as
many as 5% of hematologic malignancy patients with
pulmonary symptoms can have HPAP, while the fre-
quency increases to 10% in such patients with myeloid
disorders,6 suggesting that HPAP is not a rare cause
of respiratory illness in this patient population. Thus,
HPAP should be considered in the differential diag-
noses of all patients with hematologic malignancies
accompanied by pulmonary symptoms or abnormal
radiographs in asymptomatic patients.14 HPAP is
often diagnosed during the treatment of underlying
hematologic disorder coinciding with a prolonged per-
iod of cytopenias. However, it is known to occur up to
several years before8 development of a hematologic
disorder and while in complete remission for several
years after completion of treatment for underlying
hematologic malignancy.9 The common symptoms
of cough, dyspnea and fever are non-speciﬁc and can
easily be mistaken as pneumonia. As high as a quarter
of these patients can be asymptomatic.6
While the level of lactate dehydrogenase (LDH)
can be elevated, this is non-speciﬁc and can be due
to underlying hematologic disease or infections. No
lung-speciﬁc biological markers can be used to make
diagnosis, track disease progression or predict clinical
outcomes. One study demonstrated that the levels of
pulmonary surfactant protein D (SP-D) was elevated
in sera and BAL ﬂuid of primary PAP patients com-
pared to healthy volunteers.15 Interestingly, SP-D lev-
els were also associated with disease activity in PAP
patients. However, serum SP-D levels are also ele-
vated in other pulmonary diseases such as idiopathic
pulmonary ﬁbrosis (IPF) and interstitial pneumonia
with collagen vascular disease (IPCD) making it a
non-speciﬁc marker. On the other hand, SP-D level
in BAL ﬂuid could be more speciﬁc for PAP because
high levels of SP-D in BAL ﬂuids is seen only in
patients with PAP, but not with IPF and IPCD.15,16
No study has yet evaluated the SP-D levels in blood
or BAL in patients with HPAP and such correlative
biomarker studies are highly desirable. In the absence
of a sensitive and speciﬁc biomarker, the diagnosis of
HPAP continues to rest on invasive procedures such
as bronchoscopy, BAL, or lung biopsy. In a series of
40 HPAP patients with hematologic malignancy,
the deﬁnitive diagnosis of secondary PAP was made
using BAL in 21 cases, transbronchial lung biopsy
in 9 cases, and VATS in 10 cases.6 This means
BAL can miss the diagnosis (as was the case with
our ﬁrst BAL) in a signiﬁcant proportion of patients
and further invasive procedures such as transbronchial
lung biopsy or video-assisted lung biopsy may be131
Table 2. Reported pulmonary and extra-pulmonary opportunistic
infections in patients with PAP secondary to underlying hematologic
malignancies.
Bacterial infections
Pseudomonas aeruginosa
Mycobacterium tuberculosis
Non tuberculous Mycobacterium avium complex (MAC)a
Mycobacterium scrofulaceum
Mycobacterium abscessus
Nocardia (limited and disseminated)
Legionella pneumophila
Acinetobacter baumannii
Bacillus cereus
Staphylococcus epidermidis
Corynebacterium species
Enterococcus faecium
Enterobacter cloacae
Clostridium difficile (with toxic megacolon reported)
Viral infections
Cytomegalovirus (CMV)
Human immune deficiency virus (HIV)
Herpes simplex virus (HSV)
Parainfluenza virus
Varicella zoster virus (VZV)
Fungal infections
Pneumocystis jiroveci (carinii)a
Aspergillus fumigatusa
Cryptococcus
Histoplasma
Mucorales
Cladosporium
Trichosporon
aIndicates commonly described pulmonary infection in association with HPAP.
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required for diagnosis. The clinical course of the dis-
ease is often unpredictable due to its association with
an underlying malignancy, cytopenias from chemo-
therapy, or immunosuppressive therapy in the setting
of allo-SCT. In general, the response of an underlying
disease to therapy is associated with response to the
PAP.
An important feature of HPAP is its high suscep-
tibility to a wide range of usual pathogens and unusual
opportunistic pulmonary and extra-pulmonary infec-
tions (Table 2). Opportunistic pathogens that have
a high degree of association with HPAP include
aspergillosis (pulmonary and disseminated), nocardio-
sis (pulmonary, cerebral and disseminated) and pul-
monary and disseminated mycobacteria (mainly non-
tubercular). It is important to note that opportunistic
infections can precede, coincide or follow a diagnosis
of PAP,17 requiring continuous vigilance and high
index of suspicion and prompt intervention. The risk
of infections comes from a combination of the
immunodeﬁcient state of the hematologic malig-
nancy, chemotherapy-related cytopenias and deranged
pulmonary local immunity in the setting of PAP. In
addition, no distinctive clinical feature exists to
differentiate between PAP secondary to hematologic
malignancy, and PAP secondary to opportunistic
infection that can occur in the setting of an immuno-
compromised state such as HIV or hematologic
malignancy.
In addition, typical radiographic ﬁndings seen in
primary PAP can be absent in HPAP. Chung et al.
analyzed CT scans of the chest in seven patients with
HPAP and reported geographic ground-glass opaci-
ties (GGO) combined with septal thickening (so-
called ‘‘crazy paving’’) as predominant pattern similar
to the pattern of CT ﬁndings in primary PAP18 (Fig-
ure 1D). However, Ishii et al. showed that the most
common CT ﬁnding in secondary PAP is diffuse
ground-glass opacities (GGO) as opposed to patchy
GGO seen in primary PAP.19 In patients with hema-
tologic malignancies, these CT ﬁndings are not diag-
nostic, can easily be misinterpreted as opportunistic
infections, particularly pneumocystis or viral pneumo-
nia. Other possibilities for similar CT ﬁndings include
pulmonary edema, diffuse alveolar damage, diffuse
alveolar hemorrhage, idiopathic pneumonia syn-
drome, bronchoalveolar carcinoma, and graft-versus-
host disease in the setting of allo-SCT. It is important
that physicians suspect secondary PAP when encoun-
tered with unexplained pulmonary opacities on chest
radiograph or computed tomography in patients with
pre-existing hematological diseases. CT scan of thechest (preferably high resolution CT scan-HRCT)
is a useful tool to follow up and monitor PAP.Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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OUTCOMES OF PAP SECONDARY TO
HEMATOLOGIC MALIGNANCIES (HPAP)
In symptomatic patients with primary PAP, whole
lung lavage to physically remove the lipoproteinaceous
material is considered the traditional standard of care
leading to improved symptoms and durable prolonga-
tion of patients survival based on retrospective data.20
Subcutaneous recombinant GM-CSF and, more
recently, inhaled GM-CSF have shown responses less
complete than can be obtained with whole lung lavage.
The GM-CSF investigational modality may be con-
sidered in patients who cannot tolerate or do not
respond to whole lung lavage.21–25 Neither whole
lung lavage nor GM-CSF administration has been
uniformly effective in HPAP but the effective treat-
ment of underlying malignancies either by chemother-
apy or by hematopoietic stem cell transplantation may
lead to resolution of PAP as in our case.6,18,25,28
PAP has been described after autologous hemato-
poietic stem cell transplantation (autoSCT),26 and fol-
lowing allo-SCT utilizing matched unrelated donor
(MUD),27 matched related donor (MRD),28 and
unrelated umbilical cord blood transplantation
(UCBT).29 HPAP diagnosed prior to stem cell trans-
plantation has reported response to the successful
treatment of underlying myeloid malignancies using
autoSCT,30 reduced intensity conditioning (RIC)
allo-SCT using MRD28 and MUD,31,32 and myeloab-
lative unrelated UCBT.33 Though conditioning regi-
mens have long been suspected to play a
contributory role in PAP, these observations suggest
that neither autologous nor allogeneic transplantation
lead directly to the development of PAP, but can
induce remission for both conditions in selected
patients. Therefore, PAP should not be considered a
contraindication for hematopoietic stem cell trans-
plant, and this potentially curative treatment should
not be withheld due to concomitant PAP. However,
it is important to recognize PAP as a co-morbidityTable 3. Reported survival of patients with PAP and hematologic maligna
Reference Reported year
Cordonnier et al.5 1994
Chung et al.18 2009
Ishii et al.6 2011
Sturgess et al.31 2011
*All 3 patients had GATA2 deficiency.
Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014that can increase morbidity and mortality during and
following transplant. Elimination of the malignant
clone by a conditioning regimen and replacement of
impaired alveolar macrophages with donor stem cell-
derived normal alveolar macrophages might correct
the underlying cause of PAP. However, the safety
and efﬁcacy of allo-SCT for patients with documented
PAP should be further studied. In patients with
HPAP, RIC-allo-SCT is probably more desirable
over myeloablative conditioning regimen due to mini-
mal pulmonary toxicity and lower risk of pulmonary
infections following RIC-allo-SCT.31,32 Based on the
limited number of small retrospective observational
case series, it appears that the presence of HPAP
adversely affects outcomes of patients with hemato-
logic malignancies with median survival of less than
two years, with most deaths occurring within one year
of diagnosis5,6,18,31 (Table 3), and several deaths
attributed to respiratory failure from underlying PAP.
Optimal management of patients with PAP while
also treating a malignant blood disorder and dealing
with the complications of cancer treatment is challeng-
ing. Apart from symptomatic and supportive respira-
tory care and therapy directed toward the underlying
hematologic malignancy, no speciﬁc therapy has been
identiﬁed for the treatment of HPAP. Isolated reports
on utilizing whole lung lavage and GM-CSF while
awaiting transplant or after the transplant have shown
only modest effect.32 Due to the invasive nature of
whole lung lavage and need for frequent lavages, it is
unclear if this intervention is feasible and safe in hema-
tologic malignancy and bone marrow transplant
patients. In primary PAP, there are reports of
response using rituximab34 to decrease production of
GM-CSF autoantibodies, or plasmapheresis35 to
remove autoantibodies. There is practically no litera-
ture on using rituximab or plasmapheresis in HPAP.
Our patient was treated with a regimen that contained
rituximab leading to improvement in PAP, but the
improvement is most likely due to the clearing of the
underlying CLL and pulmonary aspergillosis ratherncies (most deaths occur within 12 months of diagnosis).
Number of patients (n) Reported survival
10 50% at 2 months
6 50% at 15 months
35 46% at 2 years
3* 33% at 2 years
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than immune effect of rituximab. Corticosteroids and
other immunosuppressant are generally tapered or dis-
continued due to their immune suppressive effects and
increased risk of opportunistic infections. However,
this approach needs to be ﬁnely balanced with the
potential ﬂare up of graft-versus-host disease
(GVHD) in the case of allo-SCT.RECENT ADVANCES AND FUTURE
DIRECTIONS OF PAP SECONDARY TO
HEMATOLOGIC MALIGNANCIES (HPAP)
While the cause of HPAP remains poorly understood,
a recent discovery of heritable GATA2 mutation asso-
ciated with early onset, sporadic and autosomal domi-
nant familial MDS and acute myeloid leukemia
(AML) has shed some light on the understanding of
this disease. Up to a third of patients who are carriers
of GATA2mutations are also affected by PAP.28,36–38
Interestingly, GATA2 mutated patients who devel-
oped PAP neither had mutations in the GM-CSF
receptor, nor had anti-GM-CSF autoantibodies.
GATA2, a zinc ﬁnger master transcription factor, is
indispensable for terminal differentiation of immature
hematopoietic cells and also plays crucial role in the
regulation of endothelial nitric oxide synthesis in pul-
monary epithelium.39,40 It is possible that some of the
pulmonary changes seen in GATA2 deﬁciency may
result from a defective endothelial nitric oxide synthase
expression, but impaired alveolar cellular immunity
appears to be the central etiology for causation of PAP
in this setting. GATA2 deﬁciency is characterized by
severe monocytopenia, B & NK-lymphocytopenia and
disseminated infections with intramacrophagic organ-
isms (e.g. mycobacteria, histoplasma).38 Interestingly,
bone marrow transplant was curative for PAP in these
patients, presumably from reconstitution of the mono-
cyte/macrophage compartment post-SCT. Holland
and Spinner assembled a cohort of 57 patients with
GATA2 deﬁciency. Ten (18%) of them developed
biopsy-proven PAP and 9/10 of these PAP patients
had underlying hematologic malignancies in the form
ofMDS (themajority), AML, or chronicmyelomonocy-
tic leukemia (e-mail communication, March 2013, with
Dr. Michael Spinner and Dr. Steven M. Holland;
National Institutes of Health, Bethesda, MD, USA).41
These ﬁndings highlight the possibility of other not
yet identiﬁed genetic susceptibilities for phenotypic
expression of PAP in hematologic malignancies not
associated with mutated GATA2.
GATA2-mutated patients may serve as potential
platform for prospective study directed to understandthe biological events leading to the development of
PAP in a signiﬁcant proportion of these patients.
The newly opened prospective observational study
Natural History Study of GATA2 Deﬁciency and
Related Disorders represents a new avenue for further
research, potentially leading to better understanding
of GATA2 deﬁciency and hopefully will also be
instrumental in providing further insights into PAP
in such patients.42 The recent discovery that most
cases of GATA2 deﬁciency are also accompanied by
a severe NK cell lymphocytopenia and marked func-
tional impairment of NK cells may also challenge
the traditional thinking of monocyte/macrophage dys-
function alone as the sole cause of PAP in patients with
hematologic malignancies and questions whether other
cellular dysfunctions (e.g. NK cell or dendritic cell
insufﬁciency) and humoral defects (e.g. cytokines other
than GM-CSF) may play a role in the development of
HPAP.43 An ongoing phase II study is evaluating allo-
SCT in patients with mutated GATA2, and in which
presence of PAP is not an exclusion criteria (e-mail
communication, May 2013, with Dennis Hickstein,
MD; NIH, Bethesda, MD, USA).44 Mutational testing
for GATA2 and appropriate consultation with the spe-
cialists at the referral center of excellence should be con-
sidered in patients with HPAP.CONCLUSION
HPAP remains a diagnostic challenge for hematolo-
gists, oncologists, transplant physicians, and allied
specialists. No guidelines exist regarding its diagnosis
and management. Most of the available literature
extrapolates diagnostic and treatment decisions based
on the literature in idiopathic PAP. Anti-GM-CSF
antibody is a valuable biomarker with high diagnostic
accuracy in idiopathic PAP, but its level is normal in
HPAP. The diagnosis of HPAP, therefore, continues
to rest on invasive modalities such as bronchoscopy,
BAL and, less commonly, lung biopsy. Though the
mechanism of HPAP remains unclear, it is important
to emphasize the reversibility of all or most pulmon-
ary function abnormalities and improved survival with
successful treatment of the underlying hematologic
malignancy and opportunistic infection. Research to
address the questions raised is limited by low inci-
dence and infrequent recognition of this condition.
Prospective multinational clinical or registry-based
studies may enhance reporting and systematic analysis
of clinicopathologic characteristics and outcomes in
this patient population.6,41Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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